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Background to the debate: The human rights responsi-
bilities of drug companies have been considered for years
by nongovernmental organizations, but were most
sharply defined in a report by the UN Special Rapporteur
on the right to health, submitted to the United Nations
General Assembly in August 2008. The ‘‘Human Rights
Guidelines for Pharmaceutical Companies in relation to
Access to Medicines’’ include responsibilities for transpar-
ency, management, monitoring and accountability, pric-
ing, and ethical marketing, and against lobbying for more
protection in intellectual property laws, applying for
patents for trivial modifications of existing medicines,
inappropriate drug promotion, and excessive pricing. Two
years after the release of the Guidelines, the PLoS Medicine
Debate asks whether drug companies are living up to
their human rights responsibilities. Sofia Gruskin and Zyde
Raad from the Harvard School of Public Health say more
assessment is needed of such responsibilities; Geralyn
Ritter, Vice President of Global Public Policy and
Corporate Responsibility at Merck & Co. argues that
multiple stakeholders could do more to help States
deliver the right to health; and Paul Hunt and Rajat
Khosla introduce Mr. Hunt’s work as the UN Special
Rapporteur on the right to the highest attainable standard
of health, regarding the human rights responsibilities of
pharmaceutical companies and access to medicines.
This is the first of three viewpoints examining the question of whether
pharmaceutical companies are living up to their human rights
responsibilities.
The Right to Health and Essential Medicines
Debate on the extent to which drug companies have human
rights obligations has elicited differing and sometimes contradic-
tory positions. As shorthand, two extremes can be cited. On one
hand, some multinational drug companies claim to support human
rights because of their philanthropic efforts such as large-scale
drug donation programs or the adoption of corporate social
responsibility (CSR) frameworks that promote, at least rhetorically,
fair labor practices and nondiscrimination in the workplace [1,2].
On the other hand, some activist groups argue that drug
companies are by their very nature constantly violating health-
related human rights, prioritizing patents and profits over people’s
access to essential and other medicines [3].
Both examples presuppose a common definition and under-
standing of human rights, and as advocacy positions, these need
not be grounded in law per se. Yet efforts to credibly assess drug
companies’ compliance with human rights norms ought to be
rooted in international legal agreements, or at least in their
commonly agreed upon interpretations. What international law
actually says is important. Perhaps most pertinent is the legally
established human right to essential medicines (EM) as a derivative
of the broader right to health [4]. Under the right to health,
governments have the legal obligation to ensure that EM are
available, accessible (including financially accessible or affordable),
acceptable, and of appropriate quality, and are advised to develop
Essential Medicines Lists using the WHO Model List as guidance.
Moreover, they must prevent rights violations committed by non-
state actors (NSAs)—including drug companies—in their jurisdic-
tions to ensure these actions do not result in inappropriate
restrictions of access to EM [4]. Examples cited include anti-
competition legislation that promotes the use of generic drugs and
the reduction of taxes imposed on generics [5–7].
What does this mean for drug companies or other NSAs like the
Bill & Melinda Gates Foundation? Surprisingly, even as the
accountability of governments under international human rights
law for making EM available is increasingly well recognized [4], to
date the relevant legal obligations of the pharmaceutical industry
and other NSAs have been inadequately addressed. Even as
concerns about access to medicines have begun to shed light on
the human rights roles and responsibilities of the pharmaceutical
industry, this discourse has been primarily in relation to
intellectual property and trade law. Given the pharmaceutical
industry’s strong influence on access to medicines and health
systems more generally [8], their specific human rights duties, as
well as those of other NSAs, require more attention.
As an increasingly important framework for government
accountability, the right to health is legally understood to
encompass only the responsibilities of NSAs. These responsibilities
are distinct from the legally binding obligations of states who sign on
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also assign legally binding obligations to drug companies, for
example by encouraging them to sign on to human rights treaties,
but it is not clear that encouraging them to assume obligations and
powers on par with governments is a good thing. While research
and debate in this area is clearly needed, even within the currently
recognized right to health responsibilities of NSAs, some
determination can already be made as to whether drug companies
are living up to their duties to support states in their obligation to
make quality EM available.
From a rights perspective, the question is how can the actions of
drug companies be more comprehensively assessed? Early
attempts to elaborate on the responsibilities of NSAs, culminating
in the 2003 UN Norms for Transnational Corporations [9,10],
give limited guidance. More recent efforts by Ruggie and Hunt to
clarify the human rights roles of businesses, and of the
pharmaceutical industry in particular, pave the way for much
needed work in this area [11–14]. We posit that concrete
assessment of the human rights responsibilities of drug companies
can be undertaken with attention to top-down, bottom-up, and
horizontal approaches.
Moving Toward Assessment of Drug Companies’
Human Rights Responsibilities: Three Approaches
Starting from the top down, one can look to see whether drug
companies are working with States in the jurisdictions where they
operate, not only to prevent direct violations of human rights but
to help States meet their legal obligations to ensure access to EM.
These activities can include promulgating and adhering to
regulations concerning drug safety and quality, which take human
rights considerations into account as well as minimizing any
potential negative health impacts of intellectual property protec-
tions [15]. Bottom-up approaches can include the governance of
public–private partnerships (PPPs) involving drug companies and
civil society organizations, and assessing their impact on human
rights and access to EM [16,17]. These bottom-up approaches can
also include analyses of drug companies’ responses to the human
rights groups’ monitoring of their actions to ensure they are in line
with legal norms and standards.
Working horizontally would examine efforts to bring together
different stakeholders as partners in shared spaces to address issues
around access to EM. Such efforts include the engagement of drug
companies in international schemes such as UNITAID and the
UN Global Compact and its working groups on human rights,
anti-corruption, and related issues, where participatory dialogue
between civil society actors, governments, and the private sector
take place [18,19]. The effectiveness of such voluntary self-
regulatory regimes for protecting or advancing human rights to
date has rightly been questioned with questions raised about poor
enforcement and self-promoting participation [20–22]. But the
lessons learned from these initial efforts can serve as a starting
point for assessment and for building accountability in future CSR
efforts such as the benchmarking of drug companies’ CSR
activities with explicit attention to human rights [23]. Horizontal
approaches to assessment would also be concerned with the extent
of the engagement of drug companies and other NSAs in PPPs,
and the extent to which these partnerships use human rights
operationally to advance access to EM and to overcome obstacles
limiting PPP success. For instance, attention to community
participation and empowerment that is supported by human
rights approaches may not only have short-term benefits for the
partners involved, but also contribute in the long-term to local
community ownership and sustainability after partnership re-
sources have been exhausted [16,17,24,25].
Lack of access to medicines continues to plague the health of
millions living in resource-poor settings. Attention to the
pharmaceutical industry’s health-related human rights responsi-
bilities has focused heavily on intellectual property, international
trade law, and the ultimate costs of drugs—ignoring many
dimensions of pharmaceuticals’ wide range of influence on health
systems and services, including national drug policies [26–28]. A
better understanding of the pharmaceutical industry’s responsibil-
ities for advancing health-related human rights, and how these are
shaped by interactions with states and NSAs, is critical to assessing
whether drug companies are living up to their human rights
responsibilities.
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